Of the 50 successfully tested carcinomas, EGFR mutations were identified in 16 cases (32%; two in exon 18, four in exon 19, two in exon 20, eight in exon 21), and KRAS mutations were identified in two (4%; two exon 2). This evidence concerns the gene EGFR and carcinoma.